Compare SUNS & FATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SUNS | FATE |
|---|---|---|
| Founded | 2023 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 108.7M | 125.6M |
| IPO Year | 2024 | 2013 |
| Metric | SUNS | FATE |
|---|---|---|
| Price | $7.55 | $2.51 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $8.75 | $4.10 |
| AVG Volume (30 Days) | 80.0K | ★ 1.7M |
| Earning Date | 05-14-2026 | 05-14-2026 |
| Dividend Yield | ★ 16.17% | N/A |
| EPS Growth | N/A | ★ 29.88 |
| EPS | ★ 0.54 | N/A |
| Revenue | ★ $21,571,434.00 | $6,646,000.00 |
| Revenue This Year | $70.81 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $14.09 | ★ N/A |
| Revenue Growth | ★ 102.96 | N/A |
| 52 Week Low | $7.34 | $0.93 |
| 52 Week High | $11.78 | $3.23 |
| Indicator | SUNS | FATE |
|---|---|---|
| Relative Strength Index (RSI) | 43.46 | 47.44 |
| Support Level | $7.38 | $1.01 |
| Resistance Level | $8.18 | $2.88 |
| Average True Range (ATR) | 0.23 | 0.18 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 42.40 | 40.00 |
Sunrise Realty Trust Inc is a real estate investment trust company. It is focus on originating CRE debt investments and providing capital to high-quality borrowers and sponsors with transitional business plans collateralized by CRE assets with opportunities for near-term value creation, as well as recapitalization opportunities. It intends to create a diversified investment portfolio, targeting investments in senior mortgage loans, mezzanine loans, whole loans, B-notes, CMBS, and debt-like preferred equity securities across CRE asset classes and investment mix to include high-quality multi-family, condominiums, retail, office, hospitality, industrial, mixed-use, and specialty-use real estate. The company's portfolio is concentrated in the Southern U.S.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. The company is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.